Monday, October 3, 2022


Biotechnology News Magazine

Keith McCormick Appointed Chief Financial Officer Lykan Bioscience: Brings 30+ Years of Financial Experience

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 15, 2021

Keith McCormick brings more than 30 years of finance experience with leadership positions in several leading companies across a range of industries, geographies, and financial disciplines.

As CFO of Lykan Bioscience, Keith will be responsible for the integrity of the company’s financial reporting and business control processes while partnering with the leadership team in all aspects of the company’s management including strategy, contracting, investment, operations management, and customer satisfaction.

Prior to joining Lykan, Keith spent 18 months consulting with emerging biotechnology companies as they scaled up operations. Prior to that, he spent 6 years with Patheon Pharmaceuticals, which was acquired by Thermo Fisher Scientific.

As VP of Finance at Patheon, he supported the global Pharmaceutical Development Services (PDS) business unit and led the initial formation of corporate FP&A and commercial finance.   Keith originates from the UK where he qualified as a Chartered Accountant and spent 20 years in hi-tech organizations in Scotland, Switzerland, Germany, and the U.S.

“Keith is a highly accomplished finance executive with extensive experience in corporate finance. He joins Lykan at a time of significant opportunity and growth for the company. His business and financial expertise will be instrumental in helping us to continue to grow the company” said Lykan Bioscience President & COO Patrick Lucy. “We are pleased to welcome Keith to the team and look forward to his leadership and contributions.”

“I am extremely excited to be joining the Lykan team and look forward to the company’s continued growth as we mature to be one of the leading cell therapy manufacturers in the industry,” said Keith McCormick.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine